Related Experiment Video
Updated: May 13, 2026
Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
Published on: July 19, 2024
Discovery of biologically active oncologic and immunologic small molecule therapies using zebrafish: overview and
Nikolaus S Trede1, William Heaton, Suzanne Ridges
1Department of Oncological Sciences, Huntsman Cancer Institute, Salt Lake City, Utah, USA.
Abstract:
Zebrafish models continue to gain popularity as in vivo models for drug discovery. Described in this overview are advantages and challenges of zebrafish drug screening, as well as a novel in vivo screen for immunomodulatory compounds using transgenic, T cell reporting zebrafish larvae designed for discovery of compounds targeting T cell leukemia. This assay system allows rapid screening of large numbers of compounds while avoiding the pitfalls of assays based on cell cultures, which lack biologic context and are afflicted by genomic instability. The rationale for this approach is based on similarities of immature normal T cells and developmentally arrested, malignant lymphoblasts in mammalian species. The screening algorithm has been used to identify a nontoxic compound with activity in both acute leukemia models and models of multiple sclerosis, demonstrating the utility of this screening procedure.
Insights
Zebrafish models offer a powerful in vivo approach for drug discovery, enabling rapid screening of immunomodulatory compounds for T cell leukemia and other diseases.
Area of Science:
- * In vivo drug discovery and development
- * Zebrafish models in translational research
Background:
- * Zebrafish models are increasingly utilized for in vivo drug screening due to their biological relevance.
- * Traditional cell culture assays for drug discovery face limitations including lack of biological context and genomic instability.
- * Immature normal T cells in zebrafish share similarities with malignant lymphoblasts in mammals, providing a rationale for their use in leukemia research.
Purpose of the Study:
- * To present an overview of the advantages and challenges associated with zebrafish drug screening.
- * To introduce a novel in vivo screening assay for immunomodulatory compounds targeting T cell leukemia using transgenic zebrafish.
- * To demonstrate the utility of this screening procedure in identifying compounds with therapeutic potential.
Main Methods:
- * Development and application of a transgenic, T cell reporting zebrafish larvae model for high-throughput screening.
- * Utilizing an in vivo assay system to rapidly screen large compound libraries.
- * Employing a screening algorithm to identify compounds with activity against T cell leukemia models.
Main Results:
- * The developed assay system allows for rapid screening of numerous compounds.
- * The system avoids the limitations of cell culture-based assays, maintaining biological context.
- * A novel nontoxic compound was identified with demonstrated activity in both acute leukemia and multiple sclerosis models.
Conclusions:
- * Zebrafish drug screening offers a robust in vivo alternative to cell-based assays.
- * The T cell reporting zebrafish model is effective for discovering immunomodulatory compounds targeting T cell leukemia.
- * This screening approach shows promise for identifying treatments for hematological malignancies and autoimmune diseases like multiple sclerosis.
